Information Provided By:
Fly News Breaks for March 28, 2016
MDT, UTHR, STDY
Mar 28, 2016 | 07:58 EDT
After the FDA rejected the premarket approval application for United Therapeutics (UTHR) and Medtronic's (MDT) implantable pump for Remodulin, RBC Capital says that the news could delay the approval of the device. The firm says that the news is "a fundamental and strategic positive" for SteadyMed's (STDY) Trevyent, whose PatchPump is now ahead of United Therapeutics and Medtronic's implantable pump, according to the firm. RBC keeps an Outperform rating on SteadyMed.
News For STDY;UTHR;MDT From the Last 2 Days
There are no results for your query STDY;UTHR;MDT